Emory University, Atlanta, GA
Dattatraya H Patil , Ella N Anastasiades , Mersiha Torlak , Aaron Lay , Mehrdad Alemozaffar , John Pattaras , Omer Kucuk , Bradley Curtis Carthon , Mehmet Asim Bilen , Kenneth Ogan , Viraj A. Master
Background: Sequential measurements of prognostic markers is an important protocol for accurate prediction of clinical outcomes in clear cell RCC. We propose that change in value of C-Reactive Protein to albumin ratio before and after surgery would be a good prognostic indicator for assessment of overall survival and risk stratification in clear cell RCC. Methods: Patients that underwent nephrectomy for clear cell RCC between 2007 and 2016 were followed up with CRP-Albumin measurements for 3 post-op visits (1, 3, 6 months). All measurements between post-op day 1 to 21 were excluded from analysis owing to possible confounding effect due to surgical stress. We assessed if change in CRP-Albumin ratio from pre-operative level is associated with any patient and tumor characteristics by fitting linear regression generalized estimating equations models to account for correlation in repeated measures. Average change in level for each post-op visit was used to stratify for an eventual end of follow-up outcome. Results: 302 clear cell RCC patients were treated with nephrectomy with mean age at surgery was 59.9±11 years, and mean BMI of 30.1± 6.6. 103 patients had at least 2 time-points available after surgery. Table 1 depicts mean CRP-Albumin ratio with 95% CI for each visit stratified with vital status. A linear GEE model fitted for baseline factors affecting change in ratio , identified t-stage, Fuhrman nuclear grade, gender, and BMI as significantly associated (p < 0.05). Conclusions: Serial measurement of CRP/Albumin ratio is useful factor for personalized risk-stratification for prognosticating overall survival as well as recurrence in patients with clear cell RCC. Significant effect of T-stage, tumor grade, and BMI depicts close relationship of CA-ratio and established risk predictors.
Pre-operative | Post-operative | |||
---|---|---|---|---|
Month 1 | Month 3 | Month 6 | ||
Dead | 2.85 (1.83-3.87) | 2.47 (0.75-4.19) | 0.22 (0.09-0.35) | 0.52 (0.04-1.07) |
Alive | 0.91 (0.58-1.25) | 0.74 (0.29-1.20) | 0.21 (0.10-0.32) | 0.18 (0.10-0.26) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2022 ASCO Annual Meeting
First Author: Andreas Bello
2024 ASCO Genitourinary Cancers Symposium
First Author: Toni K. Choueiri
2024 ASCO Genitourinary Cancers Symposium
First Author: Jeanny B. Aragon-Ching
2021 ASCO Annual Meeting
First Author: Dongjin Seo